TY  - BOOK
AU  - Yomna Mohamed Mostafa Hasan
AU  - Hanan Hasan Fouad , 
AU  - Hasan Ahmed Ali Elgarem , 
AU  - Rabab Maamoun Salama , 
TI  - Role of novel proteomic markers (apolipoprotein A1 and apolipoprotein A4) in early detection of HCC in chronic HCV infected patients / 
PY  - 2016///
CY  - Cairo : 
PB  - Yomna Mohamed Mostafa Hasan , 
KW  - Apo-A1 and Apo-A4
KW  - Hepatocellular carcinoma
KW  - Proteomic markers
N1  - Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine; Issued also as CD
N2  - Background: HCC is one of the leading causes of cancer-related deaths worldwide and the poor survival rate is largely due to late stage diagnosis. Novel proteomic markers Apo-A1 and Apo-A4 can be used in combination with other traditional markers such as AFP for an earlier and more efficient diagnosis of HCC. Aim of the work: This study was designed to detect the role of novoe proteomic markers in early detection of HCC; Apo-A1 and Apo-A4 using ELISA technique. Methods: Plasma samples were obtained from 20 HCC patients, 20 HCV-related liver cirrhosis and 20 chronic HCV patients in addition to 20 seronegative controls. Routine clinical, laboratory and ultrasonographic assessments were done. HCC was diagnosed according to AASLD (the American association for the Study of Liver Diseases) guidelines. ELISA technique was used to detect Apo-A1 and Apo-A4. RESULTS: Increased levels of Apo-A1 in HCC patients and chronic liver patients post HCV with significant difference. Decreased levels of Apo-A4 in HCC patients, Relative increase of Apo-A4 levels in chronic liver patients. Thus Apo-A1is more specific in early detection of HCC with specificity (97.5%). Concluson: Apo-A1 can be used in early detection of HCC in Chronic liver patients post HCV infection and it is more specific than Apo-A4
UR  - http://172.23.153.220/th.pdf
ER  -